← Back to Clinical Trials
Recruiting Phase 2 NCT06683014

MDMA in Borderline Personality Disorder

Trial Parameters

Condition Borderline Personality Disorder
Sponsor Yale University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2025-09-05
Completion 2026-09
Interventions
MDMA

Brief Summary

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Eligibility Criteria

Inclusion Criteria: * Adults between the ages of 18-60 years * Body weight between 110 and 210 pounds. Minimum body mass index (BMI) 16.5. * Able to swallow pills. * Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable and must sign release of information for this contact person. * People of childbearing potential must agree to utilize a highly effective method of birth control (including the following, in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) guidelines: combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation, including oral, intravaginal, and transdermal administrations; estrogen-only hormonal contraception associated with inhibition of ovulation, including oral, injectable, and implantable forms; intrauterine device (IUD); intrauterine hormone-relea

Related Trials